Search results for "Randomized controlled"

showing 10 items of 2220 documents

Covariate-constrained Randomization Routine for Achieving Baseline Balance in Cluster-randomized Trials

2017

In cluster-randomized trials, groups or clusters of individuals, rather than individuals themselves, are randomly allocated to intervention or control. In this article, we describe a new command, ccrand, that implements a covariate-constrained randomization procedure for cluster-randomized trials. It can ensure balance of one or more baseline covariates between trial arms by restriction to allocations that meet specified balance criteria. We provide a brief overview of the theoretical background, describe ccrand and its options, and illustrate it using an example.

Restricted randomizationmedicine.medical_specialtyRandomizationRandomization ProcedureComputer sciencelaw.invention03 medical and health sciences0302 clinical medicineMathematics (miscellaneous)Physical medicine and rehabilitationRandomized controlled triallawStatisticsCovariatemedicine030212 general & internal medicineBaseline (configuration management)Trial Arms030217 neurology & neurosurgeryBalance (ability)The Stata Journal: Promoting communications on statistics and Stata
researchProduct

Exercise training improves peak oxygen consumption and hemodynamics in patients with pulmonary hypertension – A prospective, randomized, controlled t…

2016

Aims: This prospective randomized controlled study investigates the effects of exercise training on peak VO 2 /kg, hemodynamics and further clinically relevant parameters in pulmonary hypertension (PH) patients. Methods: Eighty-seven patients with pulmonary arterial hypertension and inoperable chronic thromboembolic PH (54% female, 56±15years, 84% WHO functional class III/IV, 53% combination therapy) on stable disease-targeted medication were randomly assigned to a control and training group. Medication remained unchanged during the study period. Non-invasive assessments and right heart catheterization at rest and during exercise were performed at baseline and after 15 weeks. Primary endpoi…

Right heart catheterizationmedicine.medical_specialtyVentricular functionCombination therapybusiness.industryHemodynamicsmedicine.diseasePulmonary hypertensionlaw.invention03 medical and health sciences0302 clinical medicine030228 respiratory systemRandomized controlled triallawInternal medicineClinical endpointPhysical therapyCardiologyMedicineIn patient030212 general & internal medicinebusiness1.2 Rehabilitation and Chronic Care
researchProduct

Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment

2008

Liver failure is a dreaded and often fatal complication that sometimes follows a partial hepatic resection. This article reviews the definition, incidence, pathogenesis, risk factors, risk assessment, prevention, clinical features and treatment of post-resectional liver failure (PLF). A systematic, computerized search was performed using key words related to 'partial hepatic resection' and 'liver failure' to review most relevant literature about PLF published in the last 20 years. The reported incidence of PLF ranges between 0.7 and 9.1%. An inadequate quantity or quality of residual liver mass are key events in its pathogenesis. Major risk factors are the presence of comorbid conditions, p…

Risk analysismedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentmedicine.diseaseGastroenterologylaw.inventionLiver diseaseRandomized controlled triallawHepatocellular carcinomaInternal medicinemedicineLiver functionHepatectomyIntensive care medicineRisk assessmentComplicationbusinessLiver International
researchProduct

The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

2015

Background. Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting. Materials and methods. MEDLINE and EMBASE databases were searched up…

RiskCritical IllnessIntensive Care UnitCritically ill patients; Deep vein thrombosis; Meta-analysis; Outcomes; Cohort Studies; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Pulmonary Embolism; Randomized Controlled Trials as Topic; Research Design; Respiration Artificial; Risk; Thrombophilia; Treatment Outcome; Venous Thrombosis; Critical Illness; Hematology; Immunology and AllergyReviewDeep Vein Thrombosis Critically Ill Patients outcomes metanalysisCohort StudiesDeep vein thrombosiImmunology and AllergyHumansThrombophiliaMeta-analysiVenous ThrombosiHospital MortalityOutcomeRandomized Controlled Trials as TopicVenous ThrombosisHematologyLength of StayRespiration ArtificialIntensive Care UnitsTreatment OutcomeResearch DesignCritical IllneCritically ill patientCohort StudiePulmonary EmbolismHuman
researchProduct

Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis

2012

Background Routine second-look endoscopy in modern-era peptic ulcer bleeding (PUB) remains controversial. Objective To assess the effectiveness of routine second-look endoscopy in patients with PUB exhibiting high-risk stigmata after standard medical care and endoscopic therapy. Design Comprehensive literature searches (1990-2011) were performed, seeking randomized trials comparing a routine with an as-needed second endoscopy. Main Outcome Measurements The main outcome was rebleeding. Secondary outcomes were surgery and mortality. Subanalyses assessed the influence of study quality, rebleeding definitions, endoscopic hemostasis modality, and proton pump inhibitor (PPI) therapies. Analyses w…

Riskmedicine.medical_specialtymedicine.drug_classMEDLINEProton-pump inhibitorlaw.inventionRandomized controlled trialRecurrencelawOdds RatiomedicineHumansRadiology Nuclear Medicine and imagingModels Statisticalmedicine.diagnostic_testbusiness.industryHemostasis EndoscopicGastroenterologyProton Pump InhibitorsOdds ratioConfidence intervalSurgeryEndoscopyPeptic Ulcer HemorrhageTreatment OutcomeMeta-analysisHemostasisbusinessGastrointestinal Endoscopy
researchProduct

Rivaroxaban in Peripheral Artery Disease after Revascularization

2020

Abstract Background Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and ...

RivaroxabanAspirinmedicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentGeneral MedicineDisease030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trialMulticenter studylawInternal medicineCardiologyMedicine030212 general & internal medicinebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double-blind, randomized controll…

2015

OBJECTIVE: The aim of this study was to compare crestal bone-level changes, soft tissue parameters and implant success and survival between small-diameter implants made of titanium/zirconium (TiZr) alloy or of Grade IV titanium (Ti) in edentulous mandibles restored with removable overdentures. MATERIALS AND METHODS: This was a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann bone-level implants (diameter 3.3 mm), one of Ti Grade IV (control) and one of TiZr (test), in the interforaminal region. Implants were loaded after 6-8 weeks and removable Locator-retained overdentures were placed within 2 weeks of l…

RoxolidMaleSmall diameterSLActive surfaceDentistrychemistry.chemical_elementMandibleCONVENTIONAL COMPLETE DENTURESlaw.inventionDouble blindRETROSPECTIVE EVALUATION IMPLANTDouble-Blind MethodRandomized controlled triallawMARGINAL BONE LOSSHumansJaw EdentulousMedicineMANDIBULAR 2-IMPLANT OVERDENTURES610 Medicine & healthAgedDental ImplantsTitaniumPATIENT SATISFACTIONTitanium/zirconiumSTRESS-DISTRIBUTIONbusiness.industryDental Implantation Endosseoustechnology industry and agricultureWITHIN-SUBJECT COMPARISONSSoft tissueDIFFERENT LOADING PROTOCOLSDenture Overlayequipment and suppliesTitanium zirconiumddc:617.6Treatment OutcomeDental Prosthesis DesignchemistryImplant typesedentulousFemaleZirconiumImplantFINITE-ELEMENT-ANALYSISOral SurgerybusinessDental AlloysTitaniumClinical Oral Implants Research
researchProduct

Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: five-year results from a double-blind, randomized controlle…

2015

BACKGROUND The aim of this study was to compare the 5-year survival and success rates of 3.3 mm dental implants either made from titanium-zirconium (TiZr) alloy or from Grade IV titanium (Ti Grade IV) in mandibular implant-based removable overdentures. METHODS The core study had a follow-up period of 36 months and was designed as a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann Bone Level implants (diameter 3.3 mm, SLActive®), one of TiZr (test) and one of Ti Grade IV (control), in the interforaminal region. This follow-up study recruited patients from the core study and evaluated the plaque and sulcus …

RoxolidSmall diameterSplit-mouthDentistrychemistry.chemical_element610 Medicine & healthMandiblelaw.inventionTiZrDouble blindstomatognathic systemRandomized controlled trialDouble-Blind MethodlawOverdenturesAlloysMedicineHumansJaw Edentulous610 Medicine & healthGeneral DentistrySurvival rateOrthodonticsDental ImplantsTitaniumbusiness.industryDentistry(all)Ti Grade IVDental Implantation Endosseoustechnology industry and agricultureSLActiveequipment and suppliesDenture OverlayTitanium zirconiumddc:617.6stomatognathic diseaseschemistryDental Prosthesis DesignOral and maxillofacial surgeryImplantZirconiumbusinessTitaniumFollow-Up StudiesResearch Article
researchProduct

Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.

2015

Hepatocellular carcinoma is a challenging malignancy of global importance. It is the sixth most common solid malignancy and the third leading cause of cancer-related death, worldwide. Curative treatments at early stages include liver transplantation, resection and percutaneous ablation, while transarterial chemoembolization can improve survival in patients with intermediate tumor stage. Patients with mild, related symptoms and/or macrovascular invasion or extrahepatic spread are classified under the advanced stage. The standard of care in this group is sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor, whose effectiveness has been proven by 2 recent rando…

SHARPOncologyHepatocellular carcinomamedicine.medical_treatmentOLTLiver transplantationGastroenterologyLiver cirrhosilaw.inventionAntineoplastic AgentRandomized controlled triallawPractice Patterns Physicians'Randomized Controlled Trials as TopicNexavarMedicine (all)Liver NeoplasmsGastroenterologyGeneral MedicineSorafenibLocoregional therapiePercutaneous ethanol injectionLiver NeoplasmRaf kinaseHepatocellular carcinomaLiver cancerLiver cancerHumanmedicine.drugSorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsMalignancyTransarterial chemoembolizationInternal medicinemedicineCarcinomaChemotherapyHumansChemoembolization Therapeuticbusiness.industryPhenylurea CompoundsRadiofrequency ablationResectionmedicine.diseaseBCLCPercutaneous ethanol injectionbusinessDigestive diseases (Basel, Switzerland)
researchProduct

Usage and Dose Response of a Mobile Acceptance and Commitment Therapy App: Secondary Analysis of the Intervention Arm of a Randomized Controlled Trial

2016

Background: Mobile phone apps offer a promising medium to deliver psychological interventions. A mobile app based on Acceptance and Commitment Therapy (ACT) was developed and studied in a randomized controlled trial (RCT). Objective: To study usage metrics of a mobile ACT intervention and dose-response relationship between usage and improvement in psychological flexibility. Methods: An RCT was conducted to investigate the effectiveness of different lifestyle interventions for overweight people with psychological stress. This paper presents a secondary analysis of the group that received an 8-week mobile ACT intervention. Most of the analyzed 74 participants were female (n=64, 86%). Their me…

SMARTPHONE APPLICATION020205 medical informaticsretrospective studyPsychological intervention02 engineering and technologyLogistic regressionAcceptance and commitment therapy3124 Neurology and psychiatrylaw.invention0302 clinical medicinePROGRAMSRandomized controlled trialInterquartile rangelaw0202 electrical engineering electronic engineering information engineeringmobiilisovelluksetWEB-BASED ACCEPTANCEMedicine030212 general & internal medicineadherencePREDICTORSmHealthApplied Psychologyta515mobile appsT58.5-58.64DEPRESSION3. Good healthHEALTHPublic aspects of medicineRA1-1270medicine.medical_specialty515 Psychologyhyväksymis- ja omistautumisterapiaSTUDENTSHealth InformaticsContext (language use)Information technology03 medical and health sciencesNursingAcceptance and Commitment TherapyOriginal Paperbusiness.industryTillämpad psykologiSMOKING-CESSATIONConfidence interval3141 Health care scienceacceptance and commitment therapyPhysical therapyATTRITIONbusiness
researchProduct